Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
08 mars 2024 13h42 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy® based on a supplemental New Drug Application...
Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
07 mars 2024 02h00 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025. The day will be centred...
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
05 mars 2024 04h53 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to...
Novo Nordisk A/S - share repurchase programme
04 mars 2024 09h29 HE
|
Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 04 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No...
Novo Nordisk A/S - share repurchase programme
26 févr. 2024 06h02 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Notice for the Annual General Meeting of Novo Nordisk A/S
21 févr. 2024 09h03 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially...
Novo Nordisk A/S – Share repurchase programme
19 févr. 2024 09h29 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 19 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
14 févr. 2024 06h59 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 14 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S - share repurchase programme
12 févr. 2024 11h22 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 12 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12 févr. 2024 07h13 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 12 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...